Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GABRD | O14764 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174633 | 1.00 | HPGD (1.00) | HPGDFAAHEPHX2NPC1RAB9A | |
| SCHEMBL1753626 | 0.98 | HPGD (0.97) | HPGDFAAHEPHX2NPC1RAB9A | |
| SCHEMBL2667152 | 0.95 | HPGD (0.90) | HPGDFAAHEPHX2GABRDGABRA1 | |
| SCHEMBL7130857 | 0.91 | HPGD (0.83) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL14238822 | 0.91 | HPGD (0.83) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL7127339 | 0.87 | HPGD (0.77) | HPGDNPC1RAB9ALMNAPOLB | |
| SCHEMBL10862335 | 0.87 | HPGD (0.76) | HPGDFAAHEPHX2RAB9AHTT | |
| SCHEMBL10720984 | 0.85 | HPGD (0.76) | HPGDLMNAPOLBHTTALDH1A1 | |
| SCHEMBL8360507 | 0.85 | HPGD (0.73) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL12563716 | 0.85 | HPGD (0.73) | HPGDNPC1GABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021068952-A1 | BENZODIHYDROPYRAN COMPOUND TARGETING ALDO-KETO REDUCTASE 1C3 | 南京明德新药研发有限公司 | 2021-04-15 | — | — | WO | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| WO-2019204781-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DESIGN THERAPEUTICS INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-3041842-B1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| EP-1534715-B1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HPGD 140/4885FAAH 160/4885EPHX2 1296/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HPGD 140/4885FAAH 160/4885EPHX2 1296/4885 |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | HPGD 773/4885FAAH 3269/4885EPHX2 1520/4885 |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | HPGD 959/4885FAAH 4006/4885EPHX2 2650/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HPGD 477/4885FAAH 163/4885EPHX2 1157/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HPGD 140/4885FAAH 160/4885EPHX2 1296/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | HPGD 1498/4885FAAH 627/4885EPHX2 2228/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | HPGD 449/4885FAAH 4375/4885EPHX2 3465/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HPGD 140/4885FAAH 160/4885EPHX2 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.